AGCO Power Unveils Next-Generation Sustainable Powertrain Innovations at Agritechnica 2025
30.10.2025 08:00:00 CET | Business Wire | Press Release
At Agritechnica 2025 in Hanover, AGCO Power will unveil a bold vision for the future of agricultural and forestry machinery powertrain solutions—combining cutting-edge diesel technology with pioneering low-carbon innovations designed to meet the evolving needs of farmers worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251030745855/en/
Juha Heikkilä (left), Manager Electrification, holds NMC battery cells used in the prototype battery, while Kari Aaltonen, Director Engineering, stands beside the concept unit. The battery, designed by AGCO Power, contains a total of 1400 cells and offers 150 kWh of capacity.
Highlights include the newest and next‑generation CORE diesel engine family—the 8‑liter, 252 kW CORE80 powering the new 5th‑generation of the Fendt 800 Vario—alongside the AGCO Power CO₂ Calculator concept and a 150 kWh Future Battery Concept developed in‑house by AGCO Power, and cost-effective remanufactured engines that extend machine lifespans while reducing environmental impact.
AGCO Power’s innovations support farmers as they transition from fossil diesel to sustainable, low‑carbon options—and address today’s realities as well, from emissions reduction to continuous improvements in total cost of ownership.
“We believe the future of agricultural energy lies in a smart combination of fuels and technologies. There is no single solution—rather, a wider spectrum of power sources is needed. That’s why we are committed to exploring a wide range of innovations, investing significantly in R&D and our Clean Energy Lab, and promoting collaboration across the industry,” says Juha Tervala, the Vice President and Managing Director of AGCO Power.
AGCO Power designs and manufactures engines and power sources for AGCO’s world-leading tractor brands—Fendt, Massey Ferguson, and Valtra—as well as for other off-road machinery and work equipment.
AGCO Power Future Battery Concept
Making its world premiere at Agritechnica, AGCO Power’s Future Battery Concept is the company’s latest product development project. The concept battery is based on NMC cell chemistry and offers 150 kWh of capacity. The battery is designed by AGCO Power.
AGCO Power is closely tracking advances in battery cell technology and evaluating multiple chemistries, including solid‑state batteries. According to Director Engineering Kari Aaltonen, battery technology currently appears promising for agricultural applications.
“Today, the best way for a farmer to achieve emission‑free operation is with a battery‑electric driveline. Most regular farm work can, in the future, be completed with a tractor equipped with this battery. The challenge will be very long working days, but high‑power DC charging will enable operators to resume work in around 40 minutes,” says Kari Aaltonen.
Electric powertrains also offer clear advantages for work machines: lower operating costs than conventional powertrains and an almost service‑free setup. Aaltonen estimates that powertrains based on the concept battery could reach production in 5–7 years.
New CORE80 powering the new Fendt 800 Vario Gen5
At Agritechnica, the newest member of AGCO’s modern CORE diesel engine family, the CORE80, powers the new Fendt 800 Vario Gen5. As the biggest and smartest of the family, the 8‑liter CORE80 delivers even more torque (1680 Nm) and power (252 kW).
AGCO Power CORE engines have already proven top‑tier efficiency according to measurements by the independent DLG Test Centre. In the PowerMix Test 2.0 of the German Agricultural Society (DLG, Deutsche Landwirtschafts‑Gesellschaft), tractors are assessed for fuel and AdBlue consumption under typical workloads on a rolling test bench to determine overall energy efficiency.
“The combination of power and low fuel consumption makes it possible for farmers to work economically while protecting the environment,” says Roland Schmidt, Vice President, Fendt Marketing.
The smaller CORE50 and CORE75 engines will also be on display at Agritechnica. All CORE engines are manufactured at AGCO Power’s Linnavuori site in Finland. The new, low‑emission and energy‑efficient CORE engines are already in use in leading Fendt models: the 5‑liter, four‑cylinder AGCO Power CORE50 powers the Fendt 500 Vario Gen4 and Fendt 600 Vario series, while the 7.5‑liter CORE75 powers the Fendt 700 Vario Gen7 series.
AGCO Power CO₂ Calculator concept with Valtra
In collaboration with Valtra, AGCO Power will present its CO₂ Calculator concept at Agritechnica. The solution detects the type of fuel used and calculates the operational carbon footprint of agricultural machinery. It combines an engine-mounted fuel sensor with a cloud-based software solution that calculates accurate CO₂ emissions in real time. The visualized and stored data enables farmers to present verified figures to customers and supply chain partners.
“Reliable data on the operational carbon footprint is a major competitive advantage for farmers. It enables more informed decisions and allows them to track, visualize, and verify their environmental impact,” says Jarno Ratia, Director of Product Management of AGCO Power.
Agricultural traders also recognize the value of the solution. Bianca Lind, Managing Director of VERAVIS GmbH, a wholly owned subsidiary of Agravis Raiffeisen AG states:
“VERAVIS GmbH is committed to supporting farmers in meeting the requirements of the EU Green Deal while ensuring sustainable and profitable crop production. By integrating the AGCO Power CO₂ Calculator, we enhance the accuracy of our site- and crop-specific Product Carbon Footprint calculations. Validated, site-specific fuel usage data strengthens the credibility of sustainability reporting and simplifies documentation for all stakeholders—especially the farmer.”
Remanufactured engines: a cost‑effective solution for older machines
AGCO will also demonstrate at Agritechnica how the company supports farmers by remanufacturing used diesel engines to new condition. For the end user, a factory‑remanufactured engine offers fast availability as a replacement for a worn unit and significantly lower investment costs compared to a brand‑new engine.
At AGCO Power’s Linnavuori factory in Finland, a renewed remanufacturing production line has just been completed, increasing capacity from over 1,000 engines to 2,500 engines per year. This expansion supports the company’s long‑term strategy and Farmer First approach.
“Remanufacturing can lower total cost of ownership and reduce the carbon footprint versus a new machine—and, crucially, it can minimize downtime when engine problems occur. Remanufactured engines extend machine lifespans and enable up to 80% of an engine’s mass to be reused, including all cast‑iron components,” says Jussi Rinne, Director, Quality and Aftermarket.
About AGCO
AGCO (NYSE: AGCO) is a global leader in the design, manufacture and distribution of agricultural machinery and precision ag technology. AGCO delivers value to farmers and OEM customers through its differentiated brand portfolio including leading brands Fendt®, Massey Ferguson®, PTx and Valtra®. AGCO's full line of equipment, smart farming solutions and services helps farmers sustainably feed our world. Founded in 1990 and headquartered in Duluth, Georgia, USA, AGCO had net sales of approximately $11.7 billion in 2024. For more information, visit www.agcocorp.com.
About AGCO Power
AGCO Power is one of the world’s leading developers and manufacturers of engines for off-road machines. We produce engines for well-known tractor brands such as Fendt, Valtra, and Massey Ferguson. In addition to these, AGCO Power engines are used in other off-road machines, including forestry equipment. Production facilities are located in Finland, China, Brazil, and Argentina. The Linnavuori plant has been operating for over 80 years and is a subsidiary of AGCO Corporation. www.agcopower.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20251030745855/en/
Contacts
Media Contacts
Vilja Pylsy, vilja.pylsy@agcocorp.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom